Abstract:As the first member of the solute carrier 6 (SLC6) protein family, the γ-aminobutyric acid (GABA) transporter 1 (GAT1, SLC6A1 ), plays a pivotal role in the uptake of GABA from the synaptic cleft into neurons and astrocytes. This process facilitates the subsequent storage of GABA in presynaptic vesicles. The human SLC6A1 gene is highly susceptible to missense mutations, leading to severe clinical outcomes, such as epilepsy, in the afflicted patients. The molecular mechanisms of SLC6A1 -associated disorders are discerned to some degree; many SLC6A1 mutations are now known to impair protein folding, and consequently fail to reach the plasma membrane. Inherently, once inside the endoplasmic reticulum (ER), GAT1 abides by a complex cascade of events that enable efficient intracellular trafficking. This involves association with specialized molecular chaperones responsible for steering the protein folding process, oligomerization, sorting through the Golgi apparatus, and ultimately delivery to the cell surface. The entire process is subject to stringent quality control mechanisms at multiple checkpoints. While the majority of the existing loss-of-function SLC6A1 variants interfere with folding and membrane targeting, certain mutants retain abundant surface expression. In either scenario, suppressed GAT1 activity disrupts GABAergic neurotransmission, preceding the disease manifestation in individuals harboring these mutations. The nervous system is enthralling and calls for systematic, groundbreaking research efforts to dissect the precise molecular factors associated with the onset of complex neurological disorders, and uncover additional non-canonical therapeutic targets. Recent research has given hope for some of the misfolded SLC6A1 variants, which can be salvaged by small molecules, i.e., chemical and pharmacological chaperones, acting on multiple upstream targets in the secretory pathway. We here highlight the significance of pharmacochaperoning as a therapeutic strategy for the treatment of SLC6A1 -related disorders.

SLC6 neurotransmitter transporters: structure, function, and regulation

Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6

SLC6 transporters: Structure, function, regulation, disease association and therapeutics

The Functional Impact of SLC6 Transporter Genetic Variation

Monoamine transporters: vulnerable and vital doorkeepers.

General Overview of Organic Cation Transporters in Brain

A transporter's doom or destiny: SLC6A1 in health and disease, novel molecular targets and emerging therapeutic prospects

The Solute Carrier Transporters and the Brain: Physiological and Pharmacological Implications.

Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response

Regulation of monoamine transporters: Role of transporter phosphorylation

Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression

Substrate-induced Conformational Dynamics of the Dopamine Transporter

The SLC38 family of sodium–amino acid co-transporters

The SLC transporter in nutrient and metabolic sensing, regulation, and drug development

The SLC16 gene family - structure, role and regulation in health and disease

Review : Serotonin Transporter and Psychiatric Disorders: Listening to the Gene

Physiological and Pathological Functions of SLC26A6

The Effects of N-Linked Glycosylation on SLC6 Transporters

Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice

Exploring the Structural and Functional Effects of Nonsynonymous SNPs in the Human Serotonin Transporter Gene Through In Silico Approaches

Diversity of function and mechanism in a family of organic anion transporters